Knoll Capital Management’s Altimmune ALT Stock Holding History

Knoll Capital Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$493K	Sell	160,000 -961,524	-86%	-$4.08M	0.27%	33
2025 Q4	$4.05M	Hold	1,121,524	–	–	1.86%	19
2025 Q3	$4.23M	Hold	1,121,524	–	–	2.27%	17
2025 Q2	$4.34M	Hold	1,121,524	–	–	3.09%	13
2025 Q1	$5.61M	Hold	1,121,524	–	–	3.65%	7
2024 Q4	$8.09M	Hold	1,121,524	–	–	5.21%	5
2024 Q3	$6.89M	Hold	1,121,524	–	–	3.19%	9
2024 Q2	$7.46M	Buy	1,121,524 +554,305	+98%	+$4.09M	5.03%	5
2024 Q1	$5.77M	Buy	567,219 +367,219	+184%	+$3.74M	3.59%	7
2023 Q4	$2.25M	Buy	+200,000	New	+$835K	1.86%	15
2023 Q3	–	Sell	-173,864	Closed	-$614K	–	38
2023 Q2	$614K	Hold	173,864	–	–	0.74%	25
2023 Q1	$734K	Hold	173,864	–	–	1.13%	23
2022 Q4	$2.86M	Hold	173,864	–	–	6.45%	3
2022 Q3	$2.22M	Buy	173,864 +40,886	+31%	+$604K	1.3%	4
2022 Q2	$1.56M	Hold	132,978	–	–	0.89%	7
2022 Q1	$810K	Hold	132,978	–	–	0.51%	22
2021 Q4	$1.22M	Hold	132,978	–	–	0.67%	15
2021 Q3	$1.5M	Buy	132,978 +82,978	+166%	+$1.01M	0.75%	11
2021 Q2	$1.11M	Hold	50,000	–	–	0.58%	21
2021 Q1	$707K	Hold	50,000	–	–	0.46%	27
2020 Q4	$564K	Buy	+50,000	New	+$589K	0.38%	21

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Knoll Capital Management's ALT Position: Q1 2026 in Review

Knoll Capital Management reduced its Altimmune (ALT) stake by 86% in Q1 2026, selling an estimated $4.08M and leaving 160,000 shares worth $493K. The position accounts for 0.27% of the portfolio, ranked #33.

Knoll Capital Management first reported a position in ALT in Q4 2020 and has held it in 21 quarters since. The position peaked at $8.09M in Q4 2024. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

Knoll Capital Management held 160,000 shares of Altimmune worth $493K as of Q1 2026.
Knoll Capital Management sold 961,524 Altimmune shares in Q1 2026, an estimated $4.08M.
Altimmune made up 0.27% of Knoll Capital Management's portfolio in Q1 2026, its #33 holding.
Knoll Capital Management first reported a position in Altimmune in Q4 2020 and has held it in 21 quarters since.
Knoll Capital Management's Altimmune position peaked at $8.09M in Q4 2024.
173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.